Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 14, 2025 16:05 ET | Source: SeaStar Medical

SeaStar Medical Reports First Quarter 2025 Financial Results and Provides Business Updates

QUELIMMUNE adoption drives four-fold increase in sequential quarter net revenue NEUTRALIZE AKI trial exceeds 50% enrollment, triggers start of Interim AnalysisWebcast Today at 4:30 pm Eastern Time ...
November 15, 2024 08:30 ET | Source: SeaStar Medical Holding Corporation

SeaStar Medical Reaches Milestone of 100th QUELIMMUNE Commercial Device as Shipments Begin to its Third Hospital Customer

DENVER, Nov. 15, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
February 27, 2024 08:30 ET | Source: SeaStar Medical Holding Corporation

Manuscript Discussing the Benefit of SeaStar Medical’s Selective Cytopheretic Device in Patients with Heart Failure and Hyperinflammation Published in European Journal of Heart Failure

Interest continues to grow in developing new strategies to reduce systemic inflammation as a means of improving outcomes in heart failure patients DENVER, Feb. 27, 2024 (GLOBE NEWSWIRE)...
August 22, 2023 08:00 ET | Source: SeaStar Medical Holding Corporation

SeaStar Medical to Hold Business Update Conference Call Today at 4:00 p.m. Eastern Time

DENVER, Aug. 22, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce...
January 09, 2023 08:25 ET | Source: SeaStar Medical Holding Corporation

SeaStar Medical Submits Investigational Device Exemption (IDE) Application to FDA to Study a Novel Therapy to Reduce Hyperinflammation in Adult Acute Kidney Injury Patients

Building upon demonstrated clinical success, the pivotal study will evaluate the Selective Cytopheretic Device in adults with AKI requiring CKRT DENVER, Jan. 09, 2023 (GLOBE NEWSWIRE) --...
June 17, 2020 08:00 ET | Source: Kiniksa Pharmaceuticals, Ltd.

Kiniksa Announces Lancet Rheumatology Publication of Clinical Outcomes with Mavrilimumab in COVID-19

HAMILTON, Bermuda, June 17, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...